Apoptosis in Health and Disease - Part A: Volume 125

Informationen zum Autor Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Autorentext
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Inhalt

1. Apoptosis in infectious diseases as a mechanism of immune evasion and survival
   Jorge Quarleri, Cintia Cevallos, and María Victoria Delpino
2. Reactive oxygen mediated apoptosis as a therapeutic approach against opportunistic Candida albicans
   Tanu Atriwal, Meenal Chawla, Afzal Hussain, Mohamed F. Alajmi, and Mohammad Abid
3. TRPM2 channel in oxidative stress-induced mitochondrial dysfunction and apoptotic cell death
   Philippa Malko, Ran Ding, and Lin-Hua Jiang
4. Intrinsic and extrinsic pathways of apoptosis: Role in cancer development and prognosis
   Dharambir Kashyap, Vivek Kumar Garg, and Neelam Goel
5. Immunological and functional aspects of MAGEA3 cancer/testis antigen
   Biswajit Das and Shantibhusan Senapati
6. Role of histone acetyltransferase inhibitors in cancer therapy
   Muthu K. Shanmugam, Arunasalam Dharmarajan, Sudha Warrier, Anupam Bishayee, Alan Prem Kumar, Gautam Sethi, and Kwang Seok Ahn
   7. Triggering the downstream apoptotic signal inside human parasitic organisms demonstrates a promising approach for anti-parasitic drug development: A mechanistic perspective
   Nikhilesh Joardar, Niladri Mukherjee, Satyajit Halder, Kuladip Jana, and Santi P. Sinha Babu
   8. Ferulic acid-mediated modulation of apoptotic signaling pathways in cancer
   Ashutosh Gupta, Amit Kumar Singh, Mariam Loka, Abhay Kumar Pandey, and Anupam Bishayee
   9. S1PR1 signaling in cancer: A current perspective
   B. Anu, N.N. Namitha, and K.B. Harikumar
7. Phyto-drug conjugated nanomaterials enhance apoptotic activity in cancer
   Karuppaiya Vimala and Soundarapandian Kannan